#Myeloid&lymphoidneoplasmwithFIP1L1::PDGFRA|#chronic eosinophilic leukemia|aquired resistance|#T

#Myeloid and lymphoid neoplasms with eosinophilia and with the FIP1L1-PDGFRA fusion gene is the most common cause of chronic eosinophilia of clonal origin.
#Myeloid&lymphoidneoplasmwithFIP1L1::PDGFRA|#chronic eosinophilic leukemia|aquired resistance|#T674I
#Chronic eosinophilic leukaemia with FIP1L1–PDGFRA(FIP1 like 1–platelet-derived growth factor receptor alpha ) fusion.
# FIP1L1-PDGFRA p.T674I mutation originally reported as an imatinib-resistant mutation in myeloid and lymphoid neoplasms with eosinophilia with FIP1L1::PDGFRA fusion.
#Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutantion.
#T315I mutation is seen in imatinib resistant CML patients.